Re: Minerva Neurosciences to Present at JMP Securities CNS Forum
Normally companies hold back on data because they don’t want to aid competitors. For some reason, Remy pushed forward the idea during the 2nd qtr conference call that the schizophrenia 2B trial and failed 3 trial together may be enough to seek approval without another phase 3. That is such a nutty sounding point of view that is leaves me believing that there must be more to this data than what we’ve seen. We know that the placebo response was really high at week 12. I hope that they’ll be extremely transparent with all of the data from the two trials tomorrow. We need a shot in the arm. We need solid/active institutional support or a strong partner. This data is the key to that.